Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda.
Hydroxychloroquine and phlebotomy were compared in the treatment of porphyria cutanea tarda (PCT). Thirty patients received hydroxychloroquine (200 mg twice weekly) for 1 year and thirty-one underwent twice-monthly phlebotomies of 400 ml whole blood each, also for 1 year. Clinical signs of disease improved equally in both groups. At the end of the year, urinary porphyrin excretion had significantly improved in twenty-two out of thirty hydroxychloroquine-treated subjects, but in only eight out of the thirty-one patients who received phlebotomy. Liver histology showed significant regression of steatosis and siderosis in both groups compared with the pretrial biopsy, but the activity of liver disease, as judged by the extent of necrosis, inflammation and fibrosis, worsened in twelve hydroxychloroquine and in seven phlebotomy-treated patients. It is concluded that hydroxychloroquine is more effective than phlebotomy in decreasing porphyrin production. However, further work is needed to assess whether long-term hydroxychloroquine treatment favours the progression of the chronic liver disease associated with PCT.
D000328:Adult; D000368:Aged; D001815:Bloodletting; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D008107:Liver Diseases / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011164:Porphyrias / Q000378:metabolism / Q000628:therapy*; D011166:Porphyrins / Q000652:urine; D012871:Skin Diseases / Q000378:metabolism / Q000628:therapy*; D013997:Time Factors
D011166:Porphyrins; D006886:Hydroxychloroquine